Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.

Ixekizumab effectively treats generalized pustular psoriasis.

Co-trimoxazole may help treat autoimmune diseases.

Mogamulizumab can cause hair loss, often linked to a better treatment response.

Adalimumab improved folliculitis decalvans in most patients.

Adalimumab may cause severe hair loss in some patients.

Adalimumab was safe but mostly ineffective for severe alopecia areata.

MTX and GC combinations are the most effective for early rheumatoid arthritis.

The fish oil-based gel with imiquimod improves skin cancer treatment and reduces inflammation.

The drug Olumiant is now approved to treat severe hair loss from alopecia and can also be used for some hospitalized COVID-19 patients.

Adalimumab effectively stabilized severe folliculitis decalvans, preventing further hair loss and inflammation.

Switching from adalimumab to ixekizumab improved a patient's psoriasis and reversed hair whitening.

A patient lost all their hair while on rheumatoid arthritis medication.

Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.

JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.

Guselkumab significantly improves quality of life for people with moderate to severe psoriasis.

Anifrolumab may help improve symptoms in patients with overlapping autoimmune diseases.

Secukinumab and acitretin together may quickly and effectively treat severe generalized pustular psoriasis.

Methotrexate improved skin condition in 64% of patients with generalized granuloma annulare.

Adding dupilumab led to almost complete hair regrowth in a patient with alopecia areata who only partially responded to baricitinib.

Adalimumab helped control a child's severe eye disease when other treatments failed.

Talquetamab may cause hair loss and skin issues.

Erenumab significantly reduced migraine days or severity in most patients after 3 months.

Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.

A medication for skin rash also unexpectedly treated hair loss in a patient.

A man developed temporary hair loss after taking a cancer drug, which might indicate a better treatment response.

Infliximab may cause hair loss in Crohn's disease patients.

Upadacitinib improved multiple immune-related conditions in one patient.